Boston Partners Decreases Stake in Phreesia, Inc. $PHR

Boston Partners cut its holdings in Phreesia, Inc. (NYSE:PHR) by 14.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,054 shares of the company’s stock after selling 8,046 shares during the quarter. Boston Partners owned 0.08% of Phreesia worth $1,254,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Russell Investments Group Ltd. boosted its stake in shares of Phreesia by 35.4% in the first quarter. Russell Investments Group Ltd. now owns 197,848 shares of the company’s stock valued at $5,057,000 after buying an additional 51,730 shares in the last quarter. Nuveen LLC purchased a new stake in Phreesia during the first quarter worth $14,206,000. Entropy Technologies LP purchased a new stake in Phreesia during the first quarter worth $202,000. Invesco Ltd. boosted its position in Phreesia by 228.0% during the first quarter. Invesco Ltd. now owns 132,028 shares of the company’s stock worth $3,375,000 after purchasing an additional 91,779 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Phreesia by 141.3% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 89,410 shares of the company’s stock worth $2,285,000 after purchasing an additional 52,358 shares in the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PHR has been the topic of a number of research analyst reports. Truist Financial boosted their target price on Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, May 29th. Citigroup reiterated a “buy” rating on shares of Phreesia in a research report on Wednesday, May 28th. DA Davidson upgraded Phreesia to a “strong-buy” rating in a research report on Tuesday, July 22nd. KeyCorp upped their price objective on Phreesia from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, July 14th. Finally, Wall Street Zen upgraded Phreesia from a “hold” rating to a “buy” rating in a research report on Sunday, June 1st. Eleven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Phreesia currently has an average rating of “Buy” and a consensus target price of $32.27.

Phreesia Stock Up 2.6%

Shares of NYSE:PHR opened at $28.73 on Monday. The stock’s 50-day moving average price is $27.34 and its two-hundred day moving average price is $26.39. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -38.82 and a beta of 0.71.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%. The firm had revenue of $115.94 million for the quarter, compared to analyst estimates of $115.00 million. During the same period last year, the company earned ($0.05) EPS. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. On average, research analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current year.

Insider Transactions at Phreesia

In other Phreesia news, Director Mark Douglas Smith sold 7,000 shares of the firm’s stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $29.00, for a total value of $203,000.00. Following the sale, the director directly owned 37,353 shares of the company’s stock, valued at approximately $1,083,237. This trade represents a 15.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of the firm’s stock in a transaction dated Thursday, June 26th. The stock was sold at an average price of $27.67, for a total value of $77,531.34. Following the completion of the transaction, the director owned 22,037 shares in the company, valued at approximately $609,763.79. This trade represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,804 shares of company stock worth $1,510,733 in the last quarter. 5.50% of the stock is currently owned by corporate insiders.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.